These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 24991467)

  • 1. Glioblastoma multiforme: State of the art and future therapeutics.
    Wilson TA; Karajannis MA; Harter DH
    Surg Neurol Int; 2014; 5():64. PubMed ID: 24991467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological strategies for improving the prognosis of glioblastoma.
    Raj D; Agrawal P; Gaitsch H; Wicks E; Tyler B
    Expert Opin Pharmacother; 2021 Oct; 22(15):2019-2031. PubMed ID: 34605345
    [No Abstract]   [Full Text] [Related]  

  • 4. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A narrative review of research progress on drug therapies for glioblastoma multiforme.
    Zheng X; Tang Q; Ren L; Liu J; Li W; Fu W; Wang J; Du G
    Ann Transl Med; 2021 Jun; 9(11):943. PubMed ID: 34350258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of vaccine therapies for patients with glioblastoma multiforme.
    Aguilar LK; Arvizu M; Aguilar-Cordova E; Chiocca EA
    Curr Treat Options Oncol; 2012 Dec; 13(4):437-50. PubMed ID: 22903697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme.
    Bhaskaran M; Devegowda VG; Gupta VK; Shivachar A; Bhosale RR; Arunachalam M; Vaishnavi T
    ACS Chem Neurosci; 2020 Oct; 11(19):2962-2977. PubMed ID: 32945654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma multiforme: a review of where we have been and where we are going.
    Adamson C; Kanu OO; Mehta AI; Di C; Lin N; Mattox AK; Bigner DD
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1061-83. PubMed ID: 19555299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
    Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
    Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma multiforme: a review of therapeutic targets.
    Kanu OO; Mehta A; Di C; Lin N; Bortoff K; Bigner DD; Yan H; Adamson DC
    Expert Opin Ther Targets; 2009 Jun; 13(6):701-18. PubMed ID: 19409033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to overcoming immunotherapy resistance in glioblastoma.
    Gillette JS; Wang EJ; Dowd RS; Toms SA
    Front Med (Lausanne); 2023; 10():1175507. PubMed ID: 37275361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Glioblastoma Therapy: An Update on Current Approaches.
    Angom RS; Nakka NMR; Bhattacharya S
    Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.
    England B; Huang T; Karsy M
    Tumour Biol; 2013 Aug; 34(4):2063-74. PubMed ID: 23737287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
    Chin C; Lunking ES; de la Fuente M; Ayad NG
    Front Oncol; 2018; 8():521. PubMed ID: 30483476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features.
    Kim HJ; Kim DY
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33053763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?
    Veliz I; Loo Y; Castillo O; Karachaliou N; Nigro O; Rosell R
    Ann Transl Med; 2015 Jan; 3(1):7. PubMed ID: 25705639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging patents in the therapeutic areas of glioma and glioblastoma.
    Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
    Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).
    Yalamarty SSK; Filipczak N; Li X; Subhan MA; Parveen F; Ataide JA; Rajmalani BA; Torchilin VP
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.